Analysts Slash ACAD Targets After Remlifanserin Miss, But Safety Data Offers Hope
ACAD is trading near its 52-week low of $19.69 (4.9% above the low) on elevated volume (2.0× avg).
Summary
Analysts trimmed price targets across the board after remlifanserin missed its primary endpoint in Alzheimer's disease psychosis, though most kept buy ratings. The safety profile looks clean—no QT signal, no deaths, no motor or cognitive worsening—and the 60 mg dose showed growing efficacy separation over six weeks. Acadia will continue two late-stage trials, drop the 30 mg dose, and may tighten enrollment. Full data comes in November, which will determine whether the 60 mg signal holds up.
At the time of this announcement, ACAD was trading at $20.65 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.6B. The 52-week trading range was $19.69 to $30.96. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Wiseek News.